Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual)
1 Months Ended 12 Months Ended
Jul. 09, 2015
USD ($)
Sep. 12, 2013
USD ($)
Feb. 21, 2017
USD ($)
Jun. 17, 2016
USD ($)
Feb. 15, 1999
USD ($)
Dec. 31, 2017
ft²
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jul. 06, 2016
ft²
Commitments and Contingencies [Line Items]                  
Area of Land | ft²                 2,300
License Expiration Period         12 years        
License Costs   $ 50,000   $ 15,000 $ 12,500        
PaymentOfAnnualFee   $ 30,000              
Scenario, Forecast [Member]                  
Commitments and Contingencies [Line Items]                  
Operating Leases, Future Minimum Payments Due             $ 144,000 $ 170,000  
First Capital Lease Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Lease Expiration Period           3 years      
Second Capital Lease Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Lease Expiration Period           2 years      
New Valeant Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Payment For Upfront     $ 4,000,000            
Minimum [Member]                  
Commitments and Contingencies [Line Items]                  
License Costs       5,000          
Maximum [Member]                  
Commitments and Contingencies [Line Items]                  
License Costs       $ 20,000          
Licensor [Member]                  
Commitments and Contingencies [Line Items]                  
Area of Land | ft²           4,516      
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]                  
Commitments and Contingencies [Line Items]                  
Payments to Acquire Intangible Assets $ 1,000,000                
Proceeds from Sale of Intangible Assets $ 32,500,000                
Two Executive and Seven Members [Member] | New Valeant Agreement [Member] | Employee Stock Option [Member]                  
Commitments and Contingencies [Line Items]                  
Revenue Recognition, Milestone Method, Description     the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.